How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about alpelisib

    Marketing authorisation indication

    2.1 Alpelisib (Piqray, Novartis Pharmaceuticals UK) has a marketing authorisation for use 'in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy'.

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics for alpelisib.

    Price

    2.3 The company's list price is £4082.14 per 56‑pack of 150 mg film-coated tablets (BNF online, accessed March 2022). The average cost of a course of combination treatment at list price is £6,170.70 for the loading dose and £5,126.42 for the following cycles.

    The company has a commercial arrangement, which would have applied if the technology had been recommended.